Reacting to the findings, Colin Angus, professor of alcohol policy at Sheffield University Addictions Research Group, said: This looks like a reasonable study that adds to a growing body of evidence that GLP-1s may reduce alcohol-related harm
Essentially, providers should capitalize on the fact that the patient is already taking a drug that might also help with quit smoking and layer in behavioral support to help them quit and stay quit, even in the case that the GLP-1 is discontinued in the future, Brown and Leavens said
has by far the highest rate of obesity among peer nationsa third of adults (33.6%) have obesity in the U.S
Decision framework: Start existing treatments (semaglutide or tirzepatide) if: Your health risks from obesity are significant and immediate (uncontrolled diabetes, severe sleep apnea, cardiovascular disease) You have access to approved therapies through insurance or can afford them You need proven, FDA-approved medications with established safety profiles Waiting 1-2+ years for retatrutide approval doesnt align with your health timeline Consider waiting if: Youre currently at a stable weight with controlled health conditions Youve tried semaglutide or tirzepatide and hit a plateau but tolerated them well Youre in a position to potentially enroll in a retatrutide clinical trial You understand waiting means continued health risks from obesity Dont wait if: You think retatrutide will be a magic bullet with no downsides Your doctor is recommending treatment now for medical reasons Youre using waiting for the next best thing as an excuse to avoid addressing the problem The lifestyle component is non-negotiable regardless of which medication you use: High protein intake (0.7-1g per pound of body weight daily) to preserve muscle during weight loss
Store in a dry place below 25 C away from direct sunlight
Mua thuc L-Glutathione 250mg u uy tn H Ni, HCM Nu bn vn cha bit mua thuc ny chnh hng u uy tn
.png)
